Jacobio Pharmaceuticals outlicensed its phase I pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion. AstraZeneca gains global rights outside China and will jointly develop and commercialize the compound with Jacobio within China. The transaction positions AstraZeneca to expand its KRAS portfolio and gives Jacobio a partner to accelerate global development. The agreement highlights continued big‑pharma demand for early‑stage, potentially best‑in‑class oncology candidates targeting historically intractable drivers.